About IGC PHARMA, INC
IGC Pharma is a clinical-stage biotechnology company focused on advancing Alzheimer’s research through scientific innovation and technological advancements, with a lead candidate IGC-AD1 in Phase 2 clinical trials.
Development of IGC-AD1, a partial CB1 receptor agonist with anti-inflammatory action for treating agitation in Alzheimer’s patientsAI integration for early Alzheimer’s prediction and clinical decision support through the aha™ and MINT-AD platformsConducting multicenter Phase 2 clinical trials (CALMA) to evaluate the safety and efficacy of IGC-AD1
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to IGC PHARMA, INC right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.